March 31st, 2006, 1:50 pm
J, in an earlier post of this thread I mentioned optionalities involved in insurance products and their impact on the "optimal" duration strategy, i.e., surrender optionalities for the policyholder introduce a negative convexity (i.e., policyholders will repay the policy if market rates are higher than his guaranteed rate, the option the policyholder has is in the money). This negative convexity could / should (?) be hedged with payer swaptions. Unfortunately, there are usually several options embedded in insurance contracts like options to extend the contract at the current pricing, guaranteed annuity options (GAO) etc. Most insurance companies did / do not fully price these options in their contracts, either due to competitive pressure ("others do not charge for these options, we have to be competitive, we have volume targets (!)" or they just do not know / understand the value of these options. Risk management departments, driven by regulatory developments (like Solvency II), now focus on the valuation of these embedded optionalities. Also, investment departments seem to more and more take care of these options in their strategic asset allocations.